Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. was a biopharmaceutical company that operated with a focus on developing and bringing to market treatments for gastrointestinal infections and related diseases. The company was established in 1998, carving out a niche in the infectious disease sector. Its founding team included Michael N. Chang and Youli Zu. Michael N. Chang, who served as the Co-founder, President, and CEO, brought extensive experience from the pharmaceutical industry, having previously co-founded Agouron Pharmaceuticals, which was later acquired by Warner-Lambert. This background in successfully building and navigating a biopharmaceutical company to a major acquisition was instrumental in shaping Optimer's trajectory.

The company's business model centered on the discovery, development, and subsequent commercialization of novel anti-infective drugs. Optimer's primary market was the hospital and acute care setting, where it aimed to provide new solutions for challenging infections. A significant milestone for the company was the development and commercialization of DIFICID® (fidaxomicin), an antibiotic specifically designed to treat Clostridium difficile-associated diarrhea (CDAD), a serious and common hospital-acquired infection. This product represented a targeted therapeutic approach, offering a different mechanism of action compared to existing broad-spectrum antibiotics. The company's revenue stream was primarily driven by the sales of this flagship product.

The culmination of Optimer's work was its acquisition by Cubist Pharmaceuticals, Inc. in a transaction that was announced in July 2013 and finalized later that year. The deal was valued at approximately $535 million, with an additional contingent value right that could bring the total to around $801 million. This acquisition integrated Optimer's specialized portfolio, particularly DIFICID®, into Cubist's broader suite of products for the acute care environment, underscoring the strategic value of Optimer's focused research and development efforts in the biopharmaceutical landscape.

Keywords: biopharmaceutical, infectious diseases, gastrointestinal, antibiotic, fidaxomicin, Clostridium difficile, drug development, acute care, pharmaceutical acquisition, hospital infections